Aim-Induction of hepatic stellate cell (HSC) apoptosis is a viable therapeutic strategy to reduce liver fibrogenesis. Although BH3-only proteins of the Bcl-2 family trigger pro-apoptotic pathways, the BH3-only proteins mediating HSC apoptosis have not been well defined. Our aim, using proteasome inhibition as a model to induce HSC apoptosis, was to examine the BH3-only proteins contributing to cell death of this key liver cell subtype.
INTRODUCTION
Hepatic stellate cells (HSCs) are the principle source of hepatic collagen, and therefore, play a critical role in the development and maintenance of hepatic fibrosis, a nefarious consequence of all chronic liver diseases regardless of etiopathogenesis 1, 2. In health, HSCs store retinoids and generate little if any collagen3. In response to hepatic injury, these cells transform into a myofibroblast phenotype and secrete collagen. HSCs appear to undergo a commitment step to become activated and undergo limited reversion to the quiescent phenotype in vivo. Analogous to activation-induced cell death of T-lymphocytes4, activated HSCs are eliminated by apoptosis5 -7 . Thus, reversal and/or inhibition of hepatic fibrosis requires HSC apoptosis. In support of this concept, compounds which inhibit NF-B activation (a transcription factor which promotes HSC survival), such as gliotoxin or sulfasalazine, and the proteasome inhibitor bortezomib reduce hepatic fibrosis by inducing HSC apoptosis [8] [9] [10] [11] . Information regarding the cellular and molecular mechanisms regulating HSC apoptosis is limited, however, impeding the development of anti-fibrotic strategies based on inducing therapeutic HSC apoptosis.
The intrinsic pathway of apoptosis converges on mitochondria resulting in mitochondrial outer membrane permeabilization with efflux of cytochrome c and other proapoptotic proteins into the cytosol 12 . Once in the cytosol, these proteins promote caspase activation which in turn causes cellular demise 13 . The mitochondrial pathway of apoptosis is regulated by members of the Bcl-2 family of proteins 14 . Members of this family with up to four Bcl-2 homology (BH) domains, such as Bcl-2, Bcl-X L , Mcl-1 and A1, function as guardians of the mitochondria preventing apoptosis 15 . The multidomain executioners of mitochondrial dysfunction are Bax and Bak 16, 17 which directly induce mitochondrial dysfunction by permeabilizing the outer mitochondrial membrane 18 . The Bcl-2 proteins displaying sequence homology exclusively in the short BH3 domain are referred to as BH3-only proteins. These proteins are biosensors of cellular stress and induce apoptosis by functioning as intracellular death ligands, including Bad, Bid, Bik, Bim, Bmf, Hrk, Noxa and Puma 19 . The mechanisms by which they induce cell death remain unresolved, but include direct ligation and activation of Bax and/or Bak, inhibition of anti-apoptotic multi-domain Bcl-2 proteins, or both 14 . By whatever mechanism they induce cell death, BH3-only proteins are critical upstream mediators of the cell death program. The constellation of BH3-only proteins regulating cell death vary between cell types and remain incompletely understood in HSCs.
We have employed proteasome inhibitors as a model to help elucidate which Bcl-2 proteins regulate HSC apoptosis. Proteasome inhibitors rapidly induce apoptosis by complex mechanisms 20 . First, these agents prevent NF-B activation, a transcription factor necessary for maximal expression of the anti-apoptotic multidomain Bcl-2 protein A1 21 . Indeed, A1 is an important survival protein for activated HSCs as inhibition of its expression by targeted siRNA is sufficient to induce cell death of this cell type 10 . However, the BH3-only proteins participating in this process remain unclear. Although protease inhibitors enhance Bim expression, inhibition of Bim by siRNA technology does not reduce HSC apoptosis by proteasome inhibition 10 . Another BH3-only protein induced by proteasome inhibitors is Noxa [22] [23] [24] [25] [26] . Noxa is an attractive BH3-only protein inducing HSC apoptosis given its potential ability to bind A1 in vitro 27 . However, information is lacking regarding a potential role for Noxa in mediating apoptosis of HSC cells.
MATERIAL AND METHODS

Cell lines and culture
The human stellate cell line, LX-2 cells were obtained from Dr. Scott Friedman, Mt. Sinai, NY 28 . LX-2 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, GIBCO, Invitrogen, Grand Island, NY) containing high glucose (25 mM), 100,000 units/L penicillin, 100 mg/L streptomycin and 10% fetal bovine serum. Primary rat HSCs were isolated and cultured as previously described 10 .
Quantification of apoptosis
Apoptosis was quantified morphologically by assessing the characteristic nuclear changes using the DNA binding dye 4 ,6-diamidino-2-phenylindole (DAPI, Molecular Probes Inc., Eugene, OR) as previously described by us 29 . Apoptosis was also verified biochemically by measuring caspase 3/7 activity. Briefly, cells were plated in a 96-well plate (Corning Inc., Corning, NY). Caspase-3/7 activity in LX-2 cells was quantified utilizing the commercially available Apo-ONE detection assay kit (Apo-ONE homogeneous caspase-3/7 assay, Promega Corporation, Madison, WI) according to the manufacturer's instructions. Fluorescence intensity was measured using a fluorescence plate reader FLx 800 Microplate (BIO-TEK Instruments, Winooski, Vermont). The amount of fluorescent product generated is proportional to the amount of caspase-3/7 cleavage activity present in the sample and is expressed as RFU (Relative Fluorescence Units).
Immunoblot analysis
Whole cell lysates were obtained as previously described by us in detail 30 . Protein concentration of the supernatant was determined by the Bradford assay (Bio-Rad, Hercules, CA). Proteins were electrophoretically resolved by 15% SDS-PAGE and immobilized on a nitrocellulose membrane. Membranes were blocked in 5% non-fat dairy milk in Wash buffer (TBS-T; 20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween-20) was employed. Blots were incubated with primary antibodies at 4°C overnight and with secondary antibodies at room temperature for 1 hour. The following primary antibodies were used: mouse anti-hNoxa monoclonal antibody (114C307.1, dilution 1:1000, Alexis Biochemicals, Axxora Platforms, San Diego, CA), rat anti-Bim monoclonal antibody (MAB17001, 1:1000, Chemicon, Milipore Corporation, Billerica, MA), rabbit anti-Puma polyclonal antibody (3043, 1:1000, Prosci Incorporated, Poway, CA), goat anti-Bid polyclonal antibody (AF860, 1:1000, R&D System, Minneapolis, MN), rabbit anti-Bad polyclonal antibody (sc-7869, 1:1000, Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-actin polyclonal antibody (sc-1615, 1:2000, Santa Cruz Biotechnology), rabbit anti-Bik polyclonal antibody (sc-10770, 1:1000, Santa Cruz Biotechnology), rabbit anti-Bak polyclonal antibody (sc-832, 1:1000, Santa Cruz Biotechnology), rabbit anti-S-probe polyclonal antibody (sc-802, 1:1000, Santa Cruz Biotechnology), and finally, mouse monoclonal antibody to -tubulin (T6557, 1:5000, Sigma Pharmaceuticals, St. Louis, MO). Peroxidase-conjugated secondary antibodies (dilution 1:3000, Biosource International, Camarillo, CA) were used to detect antigenantibody complexes. These complexes were visualized using enhanced chemiluminescent substrate (ECL, Amersham, Arlington Heights, IL) and were exposed to Kodak X-OMAT films (Eastman Kodak, Rochester, NY). Either actin or -tubulin were used as loading controls.
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA), and reversetranscribed using random primers and Moloney leukemia virus reverse transcriptase (Invitrogen, Carlsbad, CA). PCR primers used for human Noxa were as follows: forward 5'-GCA GAG CTG GAA GTC GAG TG-3' and reverse 5'-AGC AGA AGA GTT TGG ATA TCA G-3' (yielding a 101 bp-product). Commercially available primers for ribosomal 18S RNA (Ambion, Austin, TX) were used as internal controls. Quantification of the complementary DNA template was performed with real-time polymerase chain reaction using the Light Cycler (Roche Molecular Biochemicals, Mannheim, Germany) as we have previously described in detail 29 .
Noxa mRNA and protein half-life
To examine the effect of proteasome inhibition on the half-life of Noxa mRNA, LX-2 cells were treated with media and vehicle containing 10 µmol/L MG-132 (Calbiochem, CA) in the presence or absense of 5 µmol/L actinomycin D (Sigma-Genosys, Woodlands, TX). Using this approach, at each selected time interval, total cellular RNA was isolated for RT-PCR of Noxa. To examine the effect of the proteasome inhibition on the half-life of Noxa protein, LX-2 cells were treated with vehicle in the presence and absence of MG-132 plus cyclohexamide 20 µg/ml for 0-8 hours. At the selected time interval, cells were lysed, and the lysates subjected to immunoblot analysis for Noxa as described above. Noxa and actin bands were quantified as previously described by us in detail 31 . The half-life was determined by t 1/2 = ln(2)/ , where is the decay constant.
Small interfering RNA (siRNA) experiments
RNA interference was used to silence Noxa gene expression in LX-2 cells. Noxa siRNA sense 5'-GGA GAU UUG GAG ACA SAA CUtt-3' and anti-sense 3'-AGU UUG UCU CCA AAU CUC Ctg-5' were purchased from Ambion (Austin, TX). Transient gene silencing was attained by transfection of siRNA into cells using siPORT lipid transfection reagent (Ambion) according to the manufacturer's instructions. Scrambled siRNA was used as control. Cells were transiently transfected in 6-well plates at 30% confluency. We used a final concentration of 100 nM Noxa siRNA by using 6 µL of siPORT lipid in a total transfection volume of 1 mL of OPTIMEM (Gibco-Invitrogen Corporation, Carlsbad, CA). After 3 hours of transfection, 1.5 ml of medium per well was added.
Stable transfection of S-peptide-tagged human A1 expression plasmid
The human A1 cDNA was amplified from HEL cells by rt-PCR (forward primer 5'-GTATCTGGTACCACAGACTGTGAATTTGGATAT-3 ', reverse primer 5 '-GCTACTGAATTCTCAACAGTATTGCTTCAGG-3') and subcloned into the KpnI and EcoRI sites of pSPN to yield the S peptide epitope tag fused to the N terminus of A132. The plasmid was subjected to nucleotide sequencing for confirmation. An S-peptide epitope tag was then added as previously described by us31. The plasmid was subjected to nucleotide sequencing for confirmation. Transfection with the S-peptide-tagged A1 expression plasmid was performed using a standard lipofectamine method (Life Technologies, Inc., Gaithersburg, MD). Stably transfected LX-2 clones were selected in medium containing 1200 µg/ml G418. Individual colonies were sub-cloned and screened for A1 protein expression by immunoblot analysis for the s-peptide tag. Established clones were grown in DMEM supplemented with 10% fetal bovine serum, 10% bovine calf serum, 100,000 units/ L penicillin, 100 mg/L streptomycin, and 1200 mg/L G418.
Affinity purification of S-peptide-tagged A1
Cells were lysed in buffer containing 50 mm Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1mM PMSF, 1mM Na3VO4, 100mM NaF, 20 mM microcystin, 2% CHAPS and Complete Protease Inhibitor as per manufactures protocol. Lysates (1 mL) were centrifuged at 13000 g for 15 minutes to eliminate insoluble matter. Supernatant was transferred to fresh tubes and 100 µL of S-protein Agarose (Novagen) was added. Samples were gently agitated overnight at 4°C. Samples were centrifuged at 10000 g for 1 min and supernatent discarded. Remaining S-agarose was washed 6 times with 1 mL volumes of the previous lysis buffer minus CHAPS. Following the final wash an equal volume (100 µL) of 2X Laemmli sample buffer was added. Samples were boiled for 10 minutes and resolved by SDS-PAGE and subjected to immunoblot analysis as described above.
Immunocytochemistry
Cells were cultured on 6 well plates containing coverslips. After the treatment, the medium was aspirated, and the cells were washed 3 times with phosphate-buffered saline (PBS) and then fixed with 4% paraformaldehyde in PBS containing 0.1 m PIPES, 1 mm EGTA, and 3 mm MgSO 4 for 15 min at 37 °C. After the second wash with PBS, cells were permeabilized using 0.0125% (w/v) CHAPS in PBS at room temperature for 15 min. Cells were then incubated in PBS containing 5% goat serum at room temperature for an hour. After incubation with rabbit anti-Bak NT antisera (1:300 Upstate, Lake Placid, NY) overnight at 4°C , cells were washed 3 times with PBS and incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG (Molecular Probes) for 1 h at 37 °C. Cells were then washed 3 times in PBS and 3 times in H 2 O, mounted onto slides using a ProLong Antifade kit with DAPI (Molecular Probes), and imaged by confocal microscopy with excitation and emission wavelengths of 488 and 505-580 nm (Alexa Fluor 488) and 364 and 385-470 nm (DAPI), respectively.
Reagents
DAPI, OPH-19 Q-VD-OPH, MG-132 in solution (474791) and inhibitor Bay 11-70829 were purchased from Calbiochem (La Jolla, CA). Cyclohexamide and actinomycin D (A9415) were from Sigma Pharmaceuticals (St. Louis, MO). S-protein agarose (69704) was purchased from Novagen, (San Diego, CA).
Data analysis
All data are expressed as the mean ± standard error of the mean (SEM), representing at least three separate experiments, unless otherwise specified. Analysis of variance (ANOVA) was used for comparing differences between groups and to correct for multiple comparisons, a Bonferroni post-hoc correction was employed. A p value less than 0.05 was considered statistically significant. All statistical analyses were performed using In-Stat Software (Graph Pad, San Diego, CA).
RESULTS
MG-132 treatment induce expression of Noxa protein
The proteasome inhibitor MG-132 induced apoptosis in the human HSC, LX-2 cell line, in a time-and concentration-dependent manner ( Fig. 1A and B ). Maximal apoptosis was 50-60% after 24 hour treatment with MG-132, 10 µmol/L. M G-132 cytotoxicity was caspasedependent as it was completely abrogated by the pan-caspase inhibitor QVD (Fig. 1A) .
Having established the time course and the dose dependence for MG-132-mediated LX-2 cells apoptosis, we next examined the cellular expression of BH3-only proteins. Noxa, Bim, Puma, Bad and Bid were expressed at the protein level in LX-2 cells ( Fig. 2A) . In contrast, protein expression of Bmf, Hrk and Bik was not detected by immunoblot analysis. Protein levels of Noxa and Bim increased after exposure of the cells to MG-132 ( Fig. 2A) . In particular, Noxa protein levels increased by 22-fold, as measured by densitometric analysis of immunoblots from triplicate experiments. This expression of Noxa by MG-132 treatment was observed not only in LX-2 cells but also in isolated rat primary HSCs (Fig 2B) . Since we have previously demonstrated that inhibiting Bim expression by siRNA did not prevent MG-132-mediated apoptosis 10 , we focused the remainder of this study on the role of Noxa in apoptosis by MG-132.
Noxa is up-regulated by transcriptional and post-transcriptional mechanisms
In addition to the increase in Noxa cellular protein levels during proteasome inhibition, we also observed a 16-fold increase in steady state Noxa mRNA (Fig. 3) . To ascertain whether MG-132 increased Noxa mRNA steady state levels by stabilizing Noxa mRNA, its half-life was quantified in the presence of the transcription inhibitor, actinomycin D. MG-132 treatment of LX-2 cells did not increase the half-life of Noxa mRNA (Fig. 4A) . Thus, in the absence of Actinomycin D, MG-132 increased Noxa mRNA levels by 16-fold, while in the presence of the transcriptional inhibitor, cells treated with MG-132 did not have higher Noxa mRNA levels than control (the slight decrease compared to control cells, 26% at 6 hours, was not statistically significant). Thus de novo transcription was required in order to observe increased Noxa mRNA levels in MG-132 treated cells compared to control, suggesting the increase in steady state mRNA reflected enhanced transcription. Consistent with its ability to block degradation of proteins by the proteasome, MG-132 prolonged the half-life of Noxa protein (Fig. 4B) . The calculated half-life of Noxa protein was 22 minutes, which was increased up to 20 hours in the presence of MG-132. Thus, proteasome inhibition appears to increase cellular levels of Noxa by both transcriptional and post-transcriptional mechanisms.
Noxa is essential for apoptosis by proteasome inhibition
To ascertain if Noxa is essential for mediating MG-132 apoptosis, its protein expression was knocked down using siRNA technology. First, we verified the efficacy and specificity of the siRNAs targeting Noxa. Indeed, its protein level was reduced 92% by this siRNA during proteasome treatment (Fig. 5A ). Knock down of Noxa was specific as cellular protein levels of Bim were unaltered. Having demonstrated the efficacy of Noxa siRNA in reducing Noxa cellular protein levels, cells transfected with Noxa siRNA were treated with MG-132 and apoptosis was quantified. LX-2 cells transfected with Noxa siRNA demonstrated a reduction of 54% in MG-132 cytotoxicity by both morphologic criteria and caspase-3/7 activity ( Fig.  5A and 5B) . In contrast, scrambled siRNA-transfected cells were not protected against MG-132 cytotoxicity. Taken together, these data suggest that MG-132-induced apoptosis is, in part, Noxa-dependent.
A1 partially protects LX-2 cells from apoptosis by MG-132
We have previously reported that proteasome inhibition decreased A1 mRNA expression in LX-2 cells, and further that A1 gene silencing by siRNA induced LX-2 cell death 10 . Thus, A1 acts as a mediator of LX-2 survival. To determine whether enforced expression of A1 was sufficient to protect cells treated with MG-132, we measured apoptosis in LX-2 cells stably transfected with an A1 expression plasmid (termed LX-2/A1). Compared to parental cells, LX-2/A1 cells had partial protection from MG-132-induced apoptosis (Fig. 6A ). However, protection was only partial, suggesting that A1 is functionally inhibited in cells treated with MG-132.
Noxa associates with A1 upon MG-132 treatment
It has been proposed that anti-apoptotic Bcl-2 proteins such as A1 are functionally neutralized following binding by BH3-only proteins 27 . Based on this model, we considered that the anti-apoptotic activity of A1 may be inhibited by binding to Noxa. We employed LX-2/A1 cells stably expressing S peptide-tagged A1 to ensure adequate A1 expression as well as providing an epitope tag to facilitate pulldown, given previous difficulty in using commercial antibodies for A1 immunoprecipitation. The ability of A1 to bind Noxa was then examined as described under the experimental procedure section. Affinity purification of S peptide-tagged A1 from whole cell lysates revealed binding of Noxa to this antiapoptotic protein following treatment of LX-2 cells with MG-132 ( Fig. 6B) . These data are compatible with neutralization of A1 by Noxa. A1, in part, antagonizes cell death signals by binding to the pro-apoptotic, multidomain, Bcl-2 protein Bak 14 . Therefore, we postulated that if Noxa binds A1 disabling its function, Bak would not bind as efficiently to A1. To test the A1:Bak interaction we utilized affinity purification of S peptide-tagged A1, as above, and probed the pulldown with antiserum specific for Bak. In vehicle-treated cells, A1 and Bak could be co-precipitated (Fig. 6C ). We observed a increase in S-peptide tagged A1 protein levels upon MG-132 treatment in this experiment, possibly due to decreased degradation of A1 by the proteasome. When LX-2/A1 cells were treated with MG-132, both polypeptides were recoved in higher amounts, however the Bak/A1 ratio was decreased compared to vehicle. One interpretation of these data is that Noxa binding to A1 decreased the Bak/A1 ratio, permiting Bak derepression and activation.
We next investigated Bak activation in LX-2 cells treated with MG-132. Activation of Bak can be visualized by immunofluorescent staining utilizing antiserum specific for the N terminal of Bak. This epitope is normally not accessible to the antibody for binding, however, upon activation, Bak undergoes a conformational change facilitating staining by the N terminal-specific Bak antibody 33 . Indeed, we observed Bak activation in MG-132 treated LX-2 cells (Fig. 6D) . Taken together, these data further implicate Noxa inhibition of A1 as a mechanism contributing to stellate cell death by proteasome inhibitors.
DISCUSSION
The results of this study provide new insight into the mechanisms of stellate cell apoptosis.
The results indicate that during pharmacologic proteasome inhibition: i) Noxa protein levels are increased by both transcriptional and post-translational mechanisms; ii) siRNA targeted knock down of Noxa attenuates apoptosis and iii) Noxa likely exerts its pro-apoptotic activity, in part, by binding to the anti-apoptotic protein A1 thus derepressing Bak. Each of these results is discussed in greater detail below.
Proteasome inhibition has been previously demonstrated to reduce liver injury, attenuate hepatic fibrosis, and induce stellate cell apoptosis in vivo and in vitro, respectively10 , 11. Therefore, we employed cultured HSC to continue our exploration of the mechanisms modulating HSC apoptosis. The current study focused on the BH3-only proteins involved in triggering apoptosis, as these proteins act as biosensors of cell stress and initiate the critical cellular cascades culminating in cellular demise. Of the five BH3-only proteins expressed by LX-2 cells, only two increased during proteasome inhibitor triggered apoptosis, Bim and Noxa. We have previously demonstrated that siRNA knockdown of Bim was insufficient to attenuate apoptosis in this model10; therefore, Noxa appears to be the primary BH3-only protein contributing to HSC apoptosis in this model. The increase in Noxa following proteasome inhibition was associated with an increase both in its mRNA and protein halflife. These observations suggest proteasome inhibition increases cellular Noxa levels by both transcriptional and post-translational mechanisms. Although p53 is a potent inducer of Noxa, its increase during proteasome inhibition is p53-independent 34 . Wang and co-workers have recently demonstrated that proteasome inhibition induces endoplasmic reticulum stress (unfolded protein response) which increases Noxa transcription via the transcription factors ATF3 and ATF4 35 . Fernandez et al. have also suggested that proteasome inhibition extends the half-life of Noxa22, an assumption which we were able to directly confirm. Collectively, these composite observations suggest the increase of cellular Noxa levels during proteasome inhibition is multifactorial. The concept that endoplasmic reticulum stress is a potent inducer of Noxa suggests that this mechanism of inducing Noxa and hence stellate cell apoptosis warrants further therapeutic exploration. siRNA targeted knockdown of Noxa reduced LX-2 apoptosis by the proteasome inhibitor MG-132. Prior studies have also implicated Noxa as a key mediator of apoptosis in cancer cells during proteasome inhibition 22, 23, 26, [34] [35] [36] . Thus, activated stellate cells appear to respond to proteasome inhibition much like transformed cells. This observation gives credence to the concept that when activated, stellate cells assume many features of transformed cells with enhanced proliferation, ability to migrate, and differential sensitivity to pro-apoptotic stimuli 3 .
We have previously demonstrated that survival of activated LX-2 cells is dependent upon expression of the pro-apoptotic protein A1. BH3-only proteins differentially bind to proapoptotic proteins 14 , and Noxa peptides demonstrate high affinity binding to Mcl-1 and A1 in vitro 27 . We have extended these observations by demonstrating for the first time to our knowledge binding of Noxa protein to A1 in a cellular context. Upon binding BH3-only proteins, anti-apoptotic proteins such as A1 lose their ability to repress activation of proapoptotic multidomain proteins, such as Bak 14 . Given this information, Noxa likely triggers apoptosis, in part, by binding to and inhibiting the pro-survival effect of A1 on Bak. Indeed, the Bak/A1 ratio was decreased in cells upon MG-132 treatment while Bak activation was increased. It remains possible that Noxa promotes Bak activation by additional, as yet unknown, mechanisms.
Inducing stellate cell apoptosis remains a viable therapeutic strategy for treating hepatic fibrosis 37 . Our current studies suggest that approaches to enhance Noxa expression facilitate apoptosis induction in this liver cell type. Noxa likely promotes stellate cell apoptosis by binding A1, a dominant pro-survival protein for these cells. Other cellular events likely also contribute to cellular demise in this model of cell death by proteasome inhibition. Therefore, it will be necessary to confirm these observations in other models, but if our results are confirmed in additional models, stellate cell specific Noxa expression may provide a foundation for the development of new therapeutic approaches for hepatic fibrosis. Whole cell lysates were prepared, S peptide-tagged A1 was pulled down using S proteinagarose beads. S tagged-peptide A1 was removed from the beads by boiling in Laemnli sample buffer and resolved by SDS-PAGE. Immunoblot analysis was employed to identify
